While the pharmaceutical space has been generating hefty returns for investors since the start of the year, shares of Teva Pharmaceuticals (TEVA 1.01%) are up a mere 2.7%. Compare that with Dow component Pfizer, which has soared almost 14%, and generic-drug maker Mylan, up 42% since the start of 2013, and it's clear that something serious is muting Teva's growth. In the following video from The Motley Fool's health-care show Market Checkup, analysts David Williamson and Max Macaluso discuss the major competitive threats confronting Teva today.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.